In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries

Antibiotics

MarcelaA. Radice¹  Paulo Castañeda-Méndez²  DiegoA. Jaime-Villalón³  AnaC. Gales⁴  JoséM. Munita⁵  MaríaFernanda Mojica⁶  MaríaVirginia Villegas⁶  Elsa De La Cadena⁶  TobiasManuel Appel⁶  ChristianJosé Pallares⁶ 

[1] Departamento de Microbiología, Inmunología, Biotecnología y Genética, Cátedra de Microbiología, Universidad de Buenos Aires—CONICET, Buenos Aires C1113AAD, Argentina;Department of Infectious Diseases, Hospital Médica Sur, Ciudad de México 14050, Mexico;Department of Infectious Diseases, Hospital San Angel Inn Universidad, Ciudad de México 03330, Mexico;Department of Internal Medicine, Division of Infectious Diseases, Universidade Federal de São Paulo, São Paulo 04039-032, Brazil;Genomics and Resistant Microbes (GeRM) Group, Millennium Initiative for Collaborative Research On Bacterial Resistance (MICROB-R), Santiago, Región Metropolitana 7650568, Chile;Grupo de Resistencia Antimicrobiana y Epidemiología Hospitalaria (RAEH), Universidad El Bosque, Bogotá 110121, Colombia;

关键词: antimicrobial activity;    argentina;    brazil;    chile;    colombia;    mexico;   

DOI  :  10.3390/antibiotics9020062

来源: DOAJ

【 摘 要 】

Background: High rates of resistance to third-generation cephalosporins and carbapenems in Enterobacterales have been reported in Latin America. Ceftazidime/avibactam (CZA) is the combination of a third-generation cephalosporin and a non-β-lactam β-lactamase inhibitor, which has shown activity against isolates producing class A, C and D β-lactamases. Herein, we evaluated the activity of CZA and comparators against clinical isolates of Enterobacterales in Latin America. Methods: The activity of CZA and comparators was evaluated against clinical isolates of Enterobacterales from Argentina, Brazil, Chile, Colombia and Mexico that were collected between January 2016 and October 2017. One specific phenotypic subset was evaluated. A carbapenem non-susceptible (CNS) phenotype was defined as any isolate displaying a minimum inhibitory concentration (MIC) ≥1 mg/L for ertapenem. Results: CZA was active against 95.8% of all isolates and 77.5% of CNS isolates. Fosfomycin (FOS) and tigecycline (TGC) were the second most active antibiotics with 93.4% of Enterobacterales being susceptible. Conclusions: The results of this study underline the potential therapeutic role of CZA in Latin America.

【 授权许可】

Unknown